Long-term remission in an aggressive Crooke cell adenoma of the pituitary , 18 months after discontinuation of treatment with temozolomide

Authors


Key Clinical Message

The clinical course of our patient, who sustained remission status for at least 18 months highlights the chance of long-term hormonal and tumor remission and demonstrates the efficacy and safety of discontinuation of temozolomide therapy. Prospective studies are required in order to define predictors of long-term remission of this promising therapeutic modality.

Ancillary